JP2015528449A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015528449A5 JP2015528449A5 JP2015528817A JP2015528817A JP2015528449A5 JP 2015528449 A5 JP2015528449 A5 JP 2015528449A5 JP 2015528817 A JP2015528817 A JP 2015528817A JP 2015528817 A JP2015528817 A JP 2015528817A JP 2015528449 A5 JP2015528449 A5 JP 2015528449A5
- Authority
- JP
- Japan
- Prior art keywords
- hepatitis
- pharmaceutically acceptable
- infection
- composition
- acceptable agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 84
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims description 3
- 229960003205 adefovir dipivoxil Drugs 0.000 claims description 3
- 230000007123 defense Effects 0.000 claims description 3
- 229960000980 entecavir Drugs 0.000 claims description 3
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims description 3
- 229960001627 lamivudine Drugs 0.000 claims description 3
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 3
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 claims description 3
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims 87
- 239000000203 mixture Substances 0.000 claims 80
- 208000005331 Hepatitis D Diseases 0.000 claims 42
- 208000003322 Coinfection Diseases 0.000 claims 39
- 108091034117 Oligonucleotide Proteins 0.000 claims 36
- 150000004697 chelate complex Chemical class 0.000 claims 21
- 229940079322 interferon Drugs 0.000 claims 15
- 108010050904 Interferons Proteins 0.000 claims 14
- 102000014150 Interferons Human genes 0.000 claims 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 12
- 208000006454 hepatitis Diseases 0.000 claims 12
- 231100000283 hepatitis Toxicity 0.000 claims 12
- 230000015556 catabolic process Effects 0.000 claims 10
- 238000006731 degradation reaction Methods 0.000 claims 10
- 108020004999 messenger RNA Proteins 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 229920000642 polymer Polymers 0.000 claims 10
- 102100020990 Interferon lambda-1 Human genes 0.000 claims 9
- 101710099623 Interferon lambda-1 Proteins 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 239000002773 nucleotide Substances 0.000 claims 8
- 125000003729 nucleotide group Chemical group 0.000 claims 8
- 101000793425 Homo sapiens Beta-2-glycoprotein 1 Proteins 0.000 claims 6
- 230000004048 modification Effects 0.000 claims 6
- 238000012986 modification Methods 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 5
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 5
- 108010046075 Thymosin Proteins 0.000 claims 5
- 102000007501 Thymosin Human genes 0.000 claims 5
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 5
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims 5
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 claims 4
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 4
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 4
- 108020004459 Small interfering RNA Proteins 0.000 claims 4
- 108010078233 Thymalfasin Proteins 0.000 claims 4
- 102400000800 Thymosin alpha-1 Human genes 0.000 claims 4
- 230000000840 anti-viral effect Effects 0.000 claims 4
- 239000000074 antisense oligonucleotide Substances 0.000 claims 4
- 238000012230 antisense oligonucleotides Methods 0.000 claims 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 4
- 230000003308 immunostimulating effect Effects 0.000 claims 4
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims 4
- 229960004231 thymalfasin Drugs 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108091023037 Aptamer Proteins 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 229940104302 cytosine Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- STGXGJRRAJKJRG-JDJSBBGDSA-N (3r,4r,5r)-5-(hydroxymethyl)-3-methoxyoxolane-2,4-diol Chemical compound CO[C@H]1C(O)O[C@H](CO)[C@H]1O STGXGJRRAJKJRG-JDJSBBGDSA-N 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101001002469 Homo sapiens Interferon lambda-2 Proteins 0.000 claims 1
- 108010005716 Interferon beta-1a Proteins 0.000 claims 1
- 108010005714 Interferon beta-1b Proteins 0.000 claims 1
- 102100020989 Interferon lambda-2 Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- HOOMGTNENMZAFP-NYNCVSEMSA-N [(2r,3r,5s)-2-(5-amino-2-oxo-[1,3]thiazolo[4,5-d]pyrimidin-3-yl)-5-(hydroxymethyl)oxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1C[C@@H](CO)O[C@H]1N1C(=O)SC2=CN=C(N)N=C21 HOOMGTNENMZAFP-NYNCVSEMSA-N 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 230000000157 blood function Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical group C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 229940044627 gamma-interferon Drugs 0.000 claims 1
- 230000036737 immune function Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 229960004461 interferon beta-1a Drugs 0.000 claims 1
- 229960003161 interferon beta-1b Drugs 0.000 claims 1
- 108010042414 interferon gamma-1b Proteins 0.000 claims 1
- 229940028862 interferon gamma-1b Drugs 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 239000007928 intraperitoneal injection Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 239000003970 toll like receptor agonist Substances 0.000 claims 1
- YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical class BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108700024845 Hepatitis B virus P Proteins 0.000 description 1
- 229940123066 Polymerase inhibitor Drugs 0.000 description 1
- -1 Tel defenses Jin Chemical compound 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261695040P | 2012-08-30 | 2012-08-30 | |
| US61/695,040 | 2012-08-30 | ||
| US201261703816P | 2012-09-21 | 2012-09-21 | |
| US61/703,816 | 2012-09-21 | ||
| PCT/CA2013/050377 WO2014032176A1 (en) | 2012-08-30 | 2013-05-17 | Methods for the treatment of hepatitis b and hepatitis d infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017217194A Division JP2018039834A (ja) | 2012-08-30 | 2017-11-10 | Ｂ型肝炎感染及びｄ型肝炎感染の治療組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015528449A JP2015528449A (ja) | 2015-09-28 |
| JP2015528449A5 true JP2015528449A5 (OSRAM) | 2016-06-02 |
| JP6270846B2 JP6270846B2 (ja) | 2018-01-31 |
Family
ID=50182316
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015528817A Active JP6270846B2 (ja) | 2012-08-30 | 2013-05-17 | Ｂ型肝炎感染及びｄ型肝炎感染の治療方法 |
| JP2017217194A Pending JP2018039834A (ja) | 2012-08-30 | 2017-11-10 | Ｂ型肝炎感染及びｄ型肝炎感染の治療組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017217194A Pending JP2018039834A (ja) | 2012-08-30 | 2017-11-10 | Ｂ型肝炎感染及びｄ型肝炎感染の治療組成物 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US9133458B2 (OSRAM) |
| EP (1) | EP2890403A4 (OSRAM) |
| JP (2) | JP6270846B2 (OSRAM) |
| KR (2) | KR102025679B1 (OSRAM) |
| CN (1) | CN104837501B (OSRAM) |
| AU (1) | AU2013308045B2 (OSRAM) |
| BR (1) | BR112015003985A2 (OSRAM) |
| CA (1) | CA2883785C (OSRAM) |
| CL (1) | CL2015000499A1 (OSRAM) |
| CR (1) | CR20150107A (OSRAM) |
| CU (1) | CU20150018A7 (OSRAM) |
| DO (1) | DOP2015000041A (OSRAM) |
| EC (1) | ECSP15007345A (OSRAM) |
| GT (1) | GT201500046A (OSRAM) |
| IL (1) | IL237173B (OSRAM) |
| IN (1) | IN2015DN01087A (OSRAM) |
| MX (1) | MX361522B (OSRAM) |
| MY (1) | MY172785A (OSRAM) |
| NZ (1) | NZ705730A (OSRAM) |
| PH (1) | PH12015500361B1 (OSRAM) |
| SG (1) | SG11201501255PA (OSRAM) |
| TW (1) | TWI620568B (OSRAM) |
| WO (1) | WO2014032176A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2849798T3 (da) | 2012-05-18 | 2021-05-31 | Replicor Inc | Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder |
| WO2014032176A1 (en) | 2012-08-30 | 2014-03-06 | Replicor Inc. | Methods for the treatment of hepatitis b and hepatitis d infections |
| PT3166615T (pt) * | 2014-07-10 | 2023-11-13 | Replicor Inc | Polímeros de ácidos nucleicos fosforotioados quelados para utilização em combinação com um inibidor da polimerase de hbv para o tratamento de infeções pelo vírus da hepatite b e hepatite d |
| WO2016030863A1 (en) | 2014-08-29 | 2016-03-03 | Glaxosmithkline Intellectual Property Development Limited | Compounds and methods for treating viral infections |
| US20160175245A1 (en) * | 2014-12-19 | 2016-06-23 | Mycotoxins Therapy, Llc | Treatment of diseases associated with mold and mycotoxin exposure |
| JP6924744B2 (ja) | 2015-07-17 | 2021-08-25 | アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 |
| US20170137821A1 (en) | 2015-07-17 | 2017-05-18 | Arcturus Therapeutics, Inc. | Molecules and agents for treating hepatitis b virus |
| WO2017019891A2 (en) * | 2015-07-29 | 2017-02-02 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing hepatitis b virus gene expression |
| WO2017059878A1 (en) * | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Antibodies that potently neutralize hepatitis b virus and uses thereof |
| ES3008560T3 (en) * | 2016-02-19 | 2025-03-24 | Eit Pharma Inc | Treatment of hepatitis delta virus infection with interferon lambda |
| CA3065518A1 (en) * | 2017-05-31 | 2018-12-06 | Arbutus Biopharma Corporation | Therapeutic compositions and methods for treating hepatitis b |
| TWI815887B (zh) * | 2018-05-15 | 2023-09-21 | 美商愛彼特生物製藥股份有限公司 | 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法 |
| AU2019300324A1 (en) | 2018-07-13 | 2021-01-21 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating RTEL1 expression |
| US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| FI3898668T3 (fi) | 2018-12-19 | 2023-11-28 | Humabs Biomed Sa | B-hepatiittivirusta neutraloivia vasta-aineita ja niiden käyttöjä |
| HRP20231338T1 (hr) | 2018-12-20 | 2024-02-16 | Vir Biotechnology, Inc. | Kombinirana terapija hbv |
| WO2021130266A1 (en) * | 2019-12-24 | 2021-07-01 | F. Hoffmann-La Roche Ag | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv |
| CN114507663A (zh) * | 2020-11-16 | 2022-05-17 | 浙江柏拉阿图医药科技有限公司 | 寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6030954A (en) | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
| US20040054156A1 (en) | 1992-05-14 | 2004-03-18 | Kenneth Draper | Method and reagent for inhibiting hepatitis B viral replication |
| US20030206887A1 (en) | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| US20040127446A1 (en) * | 1992-05-14 | 2004-07-01 | Lawrence Blatt | Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication |
| US5646262A (en) | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
| IL118625A0 (en) * | 1996-06-11 | 1996-10-16 | Xtl Biopharmaceuticals Limited | Anti HBV antibodies |
| CA2254931C (en) | 1996-06-11 | 2007-04-10 | Yeda Research And Development Co. Ltd. | Human monoclonal antibodies to the hepatitis b surface antigen |
| DE19725803C1 (de) | 1997-06-18 | 1999-02-11 | Deutsches Krebsforsch | HBV-gerichtete Antisense-Nukleinsäuren |
| ATE339211T1 (de) * | 2000-03-29 | 2006-10-15 | Univ Georgetown | L-fmau zur behandlung von hepatitis-delta-virus- infizierung |
| WO2004024919A1 (en) | 2002-09-13 | 2004-03-25 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
| US20070027099A1 (en) * | 2003-05-19 | 2007-02-01 | Lin Marie C | Gene therapy of HBV infection via adeno-associated viral vector mediated long term expression of small hairpin RNA (shRNA) |
| AU2004263832B2 (en) | 2003-06-12 | 2010-07-01 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| CN101084232A (zh) * | 2004-10-19 | 2007-12-05 | 里普利科股份有限公司 | 抗病毒寡核苷酸 |
| WO2011047316A1 (en) | 2009-10-16 | 2011-04-21 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Nucleic acid sequences encoding expandable hiv mosaic proteins |
| US8598334B2 (en) * | 2009-10-16 | 2013-12-03 | Glaxo Group Limited | HBV antisense inhibitors |
| CA2746981A1 (en) * | 2010-08-05 | 2012-02-05 | Replicor Inc. | Methods for inhibition of apolipoprotein h |
| SI2605794T1 (sl) | 2010-08-20 | 2017-01-31 | Replicor Inc. | Oligonukleotidni kelatni kompleksi |
| CN103889428A (zh) | 2010-10-04 | 2014-06-25 | 肝炎与病毒研究所 | 乙型肝炎病毒抗原分泌的新型抑制剂 |
| ES2856266T3 (es) | 2011-04-21 | 2021-09-27 | Glaxo Group Ltd | Modulación de la expresión del virus de la hepatitis B (VHB) |
| TWI659040B (zh) | 2011-06-30 | 2019-05-11 | 美商艾羅海德製藥公司 | 用於抑制ｂ型肝炎病毒基因表現之組合物及方法 |
| DK2849798T3 (da) | 2012-05-18 | 2021-05-31 | Replicor Inc | Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder |
| AR091065A1 (es) | 2012-05-18 | 2014-12-30 | Replicor Inc | Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral |
| WO2014032176A1 (en) | 2012-08-30 | 2014-03-06 | Replicor Inc. | Methods for the treatment of hepatitis b and hepatitis d infections |
-
2013
- 2013-05-17 WO PCT/CA2013/050377 patent/WO2014032176A1/en not_active Ceased
- 2013-05-17 EP EP13832690.5A patent/EP2890403A4/en not_active Withdrawn
- 2013-05-17 KR KR1020177032724A patent/KR102025679B1/ko not_active Expired - Fee Related
- 2013-05-17 BR BR112015003985A patent/BR112015003985A2/pt not_active Application Discontinuation
- 2013-05-17 JP JP2015528817A patent/JP6270846B2/ja active Active
- 2013-05-17 SG SG11201501255PA patent/SG11201501255PA/en unknown
- 2013-05-17 NZ NZ705730A patent/NZ705730A/en unknown
- 2013-05-17 CA CA2883785A patent/CA2883785C/en active Active
- 2013-05-17 AU AU2013308045A patent/AU2013308045B2/en active Active
- 2013-05-17 TW TW102117614A patent/TWI620568B/zh not_active IP Right Cessation
- 2013-05-17 CN CN201380045796.6A patent/CN104837501B/zh active Active
- 2013-05-17 MY MYPI2015000437A patent/MY172785A/en unknown
- 2013-05-17 KR KR1020157007858A patent/KR20150046309A/ko not_active Ceased
- 2013-05-17 IN IN1087DEN2015 patent/IN2015DN01087A/en unknown
- 2013-05-17 US US13/896,421 patent/US9133458B2/en active Active
- 2013-05-17 MX MX2015002491A patent/MX361522B/es active IP Right Grant
-
2014
- 2014-08-01 US US14/449,174 patent/US9284556B2/en active Active
- 2014-08-01 US US14/449,173 patent/US9200283B2/en active Active
-
2015
- 2015-02-10 IL IL237173A patent/IL237173B/en active IP Right Grant
- 2015-02-18 PH PH12015500361A patent/PH12015500361B1/en unknown
- 2015-02-26 DO DO2015000041A patent/DOP2015000041A/es unknown
- 2015-02-26 CU CUP2015000018A patent/CU20150018A7/es unknown
- 2015-02-27 CR CR20150107A patent/CR20150107A/es unknown
- 2015-02-27 EC ECIEPI20157345A patent/ECSP15007345A/es unknown
- 2015-02-27 CL CL2015000499A patent/CL2015000499A1/es unknown
- 2015-02-27 GT GT201500046A patent/GT201500046A/es unknown
- 2015-09-15 US US14/854,200 patent/US9533003B2/en active Active
-
2017
- 2017-11-10 JP JP2017217194A patent/JP2018039834A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015528449A5 (OSRAM) | ||
| JP6922030B2 (ja) | Ｂ型肝炎およびｄ型肝炎ウイルス感染の治療のための方法 | |
| TWI620568B (zh) | 用於治療ｂ型肝炎及ｄ型肝炎感染之方法 | |
| Ma et al. | Toward a functional cure for hepatitis B: the rationale and challenges for therapeutic targeting of the B cell immune response | |
| JP2010503396A5 (OSRAM) | ||
| JP2013522302A5 (OSRAM) | ||
| JP2009504157A5 (OSRAM) | ||
| JP2017521433A5 (OSRAM) | ||
| KR102068109B1 (ko) | 올리고뉴클레오타이드 킬레이트 복합체-폴리펩타이드 조성물 및 방법 | |
| JP2015517504A5 (OSRAM) | ||
| EP4081216A1 (en) | Method of treating virus infection using a tlr7 agonist | |
| Stein et al. | Drug targets in hepatitis B virus infection | |
| De Clercq | Interferon and its inducers—a never-ending story:“old” and “new” data in a new perspective | |
| JPWO2020036862A5 (OSRAM) | ||
| JP2022548652A (ja) | コアタンパク質アロステリックモジュレータを使用してｈｂｖ感染を処置する方法 | |
| Khan et al. | Developments in pharmacotherapeutic agents for hepatitis B–how close are we to a functional cure? | |
| Seto et al. | Future prevention and treatment of chronic hepatitis B infection | |
| CN114057816A (zh) | 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用 | |
| Deanasa et al. | The potential of antisense oligonucleotides (ASO) through inhalation based on gold nanoparticle (AuNP) delivery system in inhibiting SARS-CoV-2 replication and transcription |